Get the Stockscreener App
1.17
0.43%
-0.00
Rein Therapeutics Inc stock is traded at $1.17, with a volume of 596.20K.
It is down -0.43% in the last 24 hours and down -26.27% over the past month.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
See More
Previous Close:
$1.17
Open:
$1.17
24h Volume:
596.20K
Relative Volume:
1.39
Market Cap:
$90.92M
Revenue:
-
Net Income/Loss:
$-49.87M
P/E Ratio:
-0.5957
EPS:
-1.964
Net Cash Flow:
$-19.36M
1W Performance:
-14.02%
1M Performance:
-26.27%
6M Performance:
-27.19%
1Y Performance:
-28.53%
1-Day Range:
$1.135
$1.19
1-Week Range:
$1.00
$1.20
52-Week Range:
$1.00
$2.40
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.165 | 91.31M | 0 | -49.87M | -19.36M | -1.964 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics Prices $50 Million Public Equity Offering - TipRanks
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics, Inc.Common Stock (Nasdaq:RNTX) Stock Quote - The Chronicle-Journal
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
L. Lytton reports 4.5M shares in Rein Therapeutics (NASDAQ: RNTX) - Stock Titan
Rein Therapeutics stock dips after pricing $50M share offering - MSN
RNTX Slides As Rein Therapeutics Stock Tests New Lows - timothysykes.com
Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell - Moomoo
Rein Therapeutics | EFFECT: Others - Moomoo
RNTX Stock Slides As Traders Eye Heavy Losses - timothysykes.com
Rein Therapeutics prices $50 million public offering at $1 - Investing.com
Rein Therapeutics prices $50 million public offering at $1 By Investing.com - Investing.com South Africa
Rein Therapeutics Inc prices public offering of 50 million shares at $1.00 per share for $50 million - marketscreener.com
Rein's $50M stock sale backs Phase 2 lung fibrosis study - Stock Titan
Rein Therapeutics' 50M-Share Offering Prices at $1 a Share - Moomoo
RNTX Ownership | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
RNTX (Rein Therapeutics) shares drop 12 percent after Q4 2025 EPS misses analyst estimates by a massive margin.Crowd Breakout Signals - Newser
Rein Therapeutics provides clinical trial update for Phase 2 ReNEW Study of LTI-03 in idiopathic pulmonary fibrosis - marketscreener.com
RNTX - Finviz
Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - ChartMill
Rein Therapeutics (RNTX) to sell 30M shares to fund LTI‑03 trial - Stock Titan
Is Rein Therapeutics (RNTX) stock testing important levels | Q4 2025: Profit DisappointsCommunity Sell Signals - Newser
Rein Therapeutics, Inc. 2025 Executive Compensation, Director Pay, and Governance Details (10-K/A) - Minichart
Rein Therapeutics (NASDAQ: RNTX) details 2025 pay, ownership in 10-K/A - Stock Titan
Rein Therapeutics : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April - MarketBeat
India's HCLTech forecasts weak annual revenue growth as clients rein in discretionary spends - Yahoo Finance
Is Rein Therapeutics (RNTX) stock gaining strength (Momentum Building) 2026-04-20Fast Rising Picks - Xã Vĩnh Công
RNTX Forecast, Price Target & Analyst Ratings | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
KCK LTD. Significantly Reduces Stake in Sight Sciences Inc - GuruFocus
Why Rein Therapeutics Inc. stock is a must watch in 20262026 Earnings Surprises & Stock Timing and Entry Methods - bollywoodhelpline.com
What are bearish arguments for Rein Therapeutics (RNTX) Stock | Price at $1.54, Up 0.65%Investment Picks - Newser
FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst - defenseworld.net
PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
RNTX Should I Buy - Intellectia AI
Rein 2026 10-K Report: Business Overview, Risk Factors, Pipeline, Competition, and Strategic Partnerships - Minichart
Rein Therapeutics 10-K: $0 Revenue, $0 Gross Profit; Net Loss $49.9M - TradingView — Track All Markets
Rein Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Rein Therapeutics (NASDAQ: RNTX) 10-K shifts focus to LTI-03 and flags 2026 funding needs - stocktitan.net
Rein Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Decliners: What makes Rein Therapeutics Inc stock attractive today2026 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Risk Off: Can Rein Therapeutics Inc beat the S P 5002026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Update Recap: Can Rein Therapeutics Inc sustain earnings growthEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Returns Recap: Can RenovoRx Inc expand its profit margins2026 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Will Rein Therapeutics Inc. stock outperform international peersPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Naître et grandir
What technical signals suggest for IDAI stockBond Market & Daily Stock Trend Watchlist - Naître et grandir
Rein Therapeutics Inc Stock (RNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):